Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVX/COVID-12 Vaccine in Subjects with Prior SARS-CoV-2 Immunity
NCT05205746Phase 2Completed
- Sponsor
- Avi-Mex
- Start
- Nov 2021
- Primary completion
- Aug 2022
- Modality
- Viral Vector Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Patria in Coronavirus Disease 2019 (COVID-19), sponsored by Avi-Mex. Primary endpoints: Total titers of neutralizing anti-Spike IgG antibodies in serum at 14 days and Proportion of peripheral blood T lymphocytes that produce interferon gamma at 14 days. Started Nov 2021; status: completed.
02
Drugs
Patria
03
Conditions
Coronavirus Disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05205746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05205746.